Novo Nordisk Raises Full-Year Guidance After Strong Wegovy Pill Launch
Novo Nordisk beat expectations as its new weight-loss pill sold fast, boosting sales, prescriptions, and improving its 2026 outlook.
/ 84 items
#NVO↓
Eli Lilly Dismisses Foundayo Liver Report as 'Statistical Background Noise' — RBC Maintains Outperform
Eli Lilly states that a post-launch report of hepatic failure for Foundayo (orforglipron) is not plausibly linked to the drug. RBC Capital describes it as “statistical background noise.”
Lilly’s New Weight-Loss Pill Foundayo Gets Off to a Slow Start
Lilly’s new weight-loss pill started slow, far behind Novo’s, but it’s too early to tell which drug will win.
Agios Pharma Shares Crash as Novo Nordisk Posts Strong Phase 3 Sickle Cell Results
Novo Nordisk’s new pill cuts sickle cell pain crises, boosting outcomes and sending Agios Pharma shares down after strong trial results.
Lilly’s Foundayo Pill Launches Strong: 1,400 Prescriptions in Week 1
Eli Lilly’s new GLP-1 pill shows strong early demand, big weight loss benefits, and promising heart & diabetes results.
Novo Nordisk Teams Up with OpenAI: AI Supercharges the Fight Against Obesity
Novo Nordisk teams with OpenAI to use AI for faster drug discovery, production and sales, aiming to catch rivals like Eli Lilly.